Abstrakt

Przypisy

• 1. Alberici F., Jayne D.R.: Impact of rituximab trials on the treatmentof ANCA-associated vasculitis. Nephrol. Dial. Transplant., 2014; 29:1151-1159
  Google Scholar
• 2. Basu N., McClean A., Harper L., Amft E.N., Dhaun N., Luqmani R.A.,Little M.A., Jayne D.R., Flossmann O., McLaren J., Kumar V., Erwig L.P.,Reid D.M., Jones G.T., Macfarlane G.J.: Explaining fatigue in ANCA-associatedvasculitis. Rheumatology, 2013; 52: 1680-1685
  Google Scholar
• 3. Basu N., McClean A., Harper L., Amft E.N., Dhaun N., Luqmani R.A.,Little M.A., Jayne D.R., Flossmann O., McLaren J., Kumar V., Erwig L.P.,Reid D.M., Macfarlane G.J.: Jones G.T.: The characterisation and determinantsof quality of life in ANCA associated vasculitis. Ann. Rheum.Dis., 2014; 73: 207-211
  Google Scholar
• 4. Beck L., Bomback A.S., Choi M.J., Holzman L.B., Langford C., MarianiL.H., Somers M.J., Trachtman H., Waldman M.: KDOQI US commentaryon the 2012 KDIGO clinical practice guideline for glomerulonephritis.Am. J. Kidney Dis., 2013; 62: 403-441
  Google Scholar
• 5. Berden A.E., Ferrario F., Hagen E.C., Jayne D.R., Jennette J.C., Joh K.,Neumann I., Noël L.H., Pusey C.D., Waldherr R., Bruijn J.A., Bajema I.M.:Histopathologic classification of ANCA-associated glomerulonephritis.J. Am. Soc. Nephrol., 2010; 21: 1628-1636
  Google Scholar
• 6. Berden A., Göçeroglu A., Jayne D., Luqmani R., Rasmussen N., BruijnJ.A., Bajema I. Diagnosis and management of ANCA associated vasculitis.BMJ, 2012; 344: e26
  Google Scholar
• 7. Birck R., Warnatz K., Lorenz H.M., Choi M., Haubitz M., Grünke M.,Peter H.H., Kalden J.R., Göbel U., Drexler J.M., Hotta O., Nowack R., VanDer Woude F.J.: 15-Deoxyspergualin in patients with refractory ANCA–associated systemic vasculitis: a six-month open-label trial to evaluatesafety and efficacy. J. Am. Soc. Nephrol., 2003; 14: 440-447
  Google Scholar
• 8. Bomback A.S., Appel G.B., Radhakrishnan J., Shirazian S., Herlitz L.C.,Stokes B., D’Agati V.D., Markowitz G.S.: ANCA-associated glomerulonephritisin the very elderly. Kidney Int., 2011; 79: 757-764
  Google Scholar
• 9. Bontscho J., Schreiber A., Manz R.A., Schneider W., Luft F.C., KettritzR.: Myeloperoxidase-specific plasma cell depletion by bortezomib protectsfrom antineutrophil cytoplasmic autoantibodies-induced glomerulonephritis.J. Am. Soc. Nephrol., 2011; 22: 336-348
  Google Scholar
• 10. Brix S.R., Krebs C., Noriega M., Janneck M., Iking-Konert C., WiechT., Panzer U., Stahl R.A.: CCL 18 in relapsing ANCA-associated necrotizingglomerulonephritis. Nephron, 2015; 129: 112-113 (17th InternationalVasculitis & ANCA Workshop)
  Google Scholar
• 11. Buhaescu I., Yood R.A., Izzedine H.: Serum procalcitonin in systemicautoimmune diseases – where are we now? Semin. ArthritisRheum., 2010; 40: 176-183
  Google Scholar
• 12. Bunch D.O., Mendoza C.E., Aybar.L.T., Kotzen E.S., Colby K.R., Hu Y.,Hogan.SL., Poulton C.J., Schmitz J.L., Falk R.J., Nachman P.H., PendergraftW.F., McGregor J.G.: Gleaning relapse risk from B cell phenotype:decreased CD5+ B cells portend a shorter time to relapse after B celldepletion in patients with ANCA-associated vasculitis. Ann. Rheum.Dis., 2015; 74: 1784-1786
  Google Scholar
• 13. Calich A.L., Puéchal X., Pugnet G., London J., Terrier B., CharlesP., Mouthon L., Guillevin L.: Rituximab for induction and maintenancetherapy in granulomatosis with polyangiitis (Wegener’s). Resultsof a single-center cohort study on 66 patients. J. Autoimmun., 2014;50: 135-141
  Google Scholar
• 14. Carpenter D.M., Kadis J.A., Devellis R.F., Hogan S.L., Jordan J.M.: Theeffect of medication-related support on the quality of life of patientswith vasculitis in relapse and remission. J. Rheumatol., 2011; 38: 709-715
  Google Scholar
• 15. Carson K.R., Evens A.M., Richey E.A., Habermann T.M., Focosi D.,SeymourJ.F., Laubach J., Bawn S.D., Gordon L.I., Winter J.N., FurmanR.R., VoseJ.M., Zelenetz A.D., Mamtani R., Raisch D.W., et al.: Progressivemultifocal leukoencephalopathy after rituximab therapy in HIV-negativepatients: a report of 57 cases from the Research on Adverse DrugEvents and Reports project. Blood, 2009;113: 4834-4840
  Google Scholar
• 16. Cartin-Ceba R., Golbin J.M., Keogh K.A., Peikert T., Sánchez-MenéndezM., Ytterberg S.R., Fervenza F.C., Specks U.: Rituximab for remissioninduction and maintenance in refractory granulomatosis with polyangiitis(Wegener’s): ten-year experience at a single center. ArthritisRheum., 2012; 64: 3770-3778
  Google Scholar
• 17. CCX168 Phase II Data in ANCA-Associated Renal Vasculitis. http://ir.chemocentryx.com/releasedetail.cfm?ReleaseID=811237 (28.02.2016)
  Google Scholar
• 18. de Groot K., Harper L., Jayne D.R., Flores Suarez L.F., Gregorini G.,Gross W.L., Luqmani R., Pusey C.D., Rasmussen N., Sinico R.A., Tesar V.,Vanhille P., Westman K., Savage C.O.: Pulse versus daily oral cyclophosphamidefor induction of remission in antineutrophil cytoplasmicantibody-associated vasculitis: a randomized trial. Ann. Intern. Med.,2009; 150: 670-680
  Google Scholar
• 19. de Groot K., Rasmussen N., Bacon P.A., Tervaert J.W., Feighery C.,Gregorini G., Gross W.L., Luqmani R., Jayne D.R.: Randomized trial ofcyclophosphamide versus methotrexate for induction of remission inearly systemic antineutrophil cytoplasmic antibody-associated vasculitis.Arthritis Rheum., 2005; 52: 2461-2469
  Google Scholar
• 20. de Joode A.A., Sanders J.S., Smid W.M., Stegeman C.A.: Plasmapheresisrescue therapy in progressive systemic ANCA-associated vasculitis:single-center results of stepwise escalation of immunosuppression.J. Clin. Apher., 2014; 29: 266-272
  Google Scholar
• 21. Draibe J., Poveda R., Fulladosa X., Vidaller A., Zulberti C., Goma M.,Pujol R., Ripoll E., Torras J., Grinyó J.M.: Use of mycophenolate in ANCA-associatedrenal vasculitis: 13 years of experience at a universityhospital. Nephrol. Dial.Transplant., 2015; 30: 132-137
  Google Scholar
• 22. Eisenberger U., Fakhouri F., Vanhille P., Beaufils H., Mahr A., GuillevinL., Lesavre P., Noël L.H.: ANCA-negative pauci-immune renalvasculitis: histology and outcome. Nephrol. Dial. Transplant., 2005;20: 1392-1399
  Google Scholar
• 23. European Vasculitis Study Group. Clinical Trial Protocol: REMAIN.http://www.vasculitis.org/images/documents/remain%20jan%202006.pdf (28.02.2016)
  Google Scholar
• 24. Falk R.J.: Identification and management of relapsing disease ingranulomatosis with polyangiitis and microscopic polyangiitis. In:UpToDate, eds.: R.J. Glassock, G.B. Appel. UpToDate, Waltham, Massachusetts
  Google Scholar
• 25. Falk R.J.: Maintenance immunosuppressive therapy in granulomatosiswith polyangiitis and microscopic polyangiitis. In: UpToDate,eds.: G.B. Appel, F.C.Fervenza. UpToDate, Waltham, Massachusetts
  Google Scholar
• 26. Falk R.J.: Prognosis in granulomatosis with polyangiitis and microscopicpolyangiitis,and management of those who develop end-stagerenal disease. In: UpToDate, eds.: G.B. Appel, F.C. Fervenza. UpToDate,Waltham, Massachusetts
  Google Scholar
• 27. Flossmann O., Baslund B., Bruchfeld A., Tervaert J.W., Hall C., HeinzelP., Hellmich B., Luqmani R.A., Nemoto K., Tesar V., Jayne D.R.: Deoxyspergualin in relapsing and refractory Wegener’s granulomatosis.Ann. Rheum. Dis., 2009; 68: 1125-1130
  Google Scholar
• 28. Flossmann O., Berden A., de Groot K., Hagen C., Harper L., HeijlC., Höglund P., Jayne D., Luqmani R., Mahr A., Mukhtyar C., Pusey C.,Rasmussen N., Stegeman C., Walsh M., et al.: Long-term patient survivalin ANCA-associated vasculitis. Ann. Rheum. Dis. 2011; 70: 488-494
  Google Scholar
• 29. Furuta S., Jayne D.R.: Antineutrophil cytoplasm antibody-associatedvasculitis: recent developments. Kidney Int., 2013; 84: 244-249
  Google Scholar
• 30. Galesic K., Ljubanovic D., Horvatic I.: Treatment of renal manifestationsof ANCA-associated vasculitis. J. Nephropathol., 2013; 2: 6-19
  Google Scholar
• 31. Geetha D., Specks U., Stone J.H., Merkel P.A., Seo P., Spiera R., LangfordC.A., Hoffman G.S., Kallenberg C.G., St Clair E.W., Fessler B.J., DingL., Tchao N.K., Ikle D., et al.. Rituximab versus cyclophosphamide forANCA-associated vasculitis with renal involvement. J. Am. Soc. Nephrol.,2015; 26: 976-985
  Google Scholar
• 32. Gigante A., Gasperini M.L., Barbano B., Liberatori M., Sardo L., JovanovicT., Giannakakis K., Cianci R., Amoroso A.: Gabexate mesylateas treatment in the course of ANCA-negative microscopic polyangiitis.Ren. Fail., 2013; 35: 721-724
  Google Scholar
• 33. Gregersen J.W., Kristensen T., Krag S.R., Birn H., Ivarsen P.: Earlyplasma exchange improves outcome in PR3-ANCA-positive renal vasculitis.Clin. Exp. Rheumatol., 2012; 30: S39-S47
  Google Scholar
• 34. Guerry M.J., Brogan P., Bruce I.N., D’Cruz D.P., Harper L., Luqmani R.,Pusey C.D., Salama A.D., Scott D.G., Savage C.O., Watts R.A., Jayne D.R.:Recommendations for the use of rituximab in anti-neutrophil cytoplasmantibody-associated vasculitis. Rheumatology, 2012; 51: 634-643
  Google Scholar
• 35. Guillevin L., Pagnoux C., Karras A., Khouatra C, Aumaître O, CohenP, Maurier F, Decaux O., Ninet J., Gobert P., Quémeneur T., Blanchard–Delaunay C., Godmer P., Puéchal X., Carron P.L., et al.: Rituximab versusazathioprine for maintenance in ANCA-associated vasculitis. N. Engl.J. Med., 2014; 371: 1771-1780
  Google Scholar
• 36. Han F., Liu G., Zhang X, Li X., He Q., He X., Li Q., Wang S., Wang H.,Chen J.: Effects of mycophenolate mofetil combined with corticosteroidsfor induction therapy of microscopic polyangiitis. Am. J. Nephrol.,2011; 33: 185-192
  Google Scholar
• 37. Harper L., Morgan M.D., Walsh M., Hoglund P., Westman K., FlossmannO., Tesar V., Vanhille P., de Groot K., Luqmani R., Flores-SuarezL.F., Watts R., Pusey C., Bruchfeld A., Rasmussen N., et al.: Pulse versusdaily oral cyclophosphamide for induction of remission in ANCA–associated vasculitis: long-term follow-up. Ann. Rheum. Dis., 2012;71: 955-960
  Google Scholar
• 38. Harper L., Savage C.O.: ANCA-associated renal vasculitis at the endof the twentieth century – a disease of older patients. Rheumatology,2005; 44: 495-501
  Google Scholar
• 39. Hasegawa M., Hattori K., Sugiyama S., Asada H., Yamashita H.,Takahashi K., Hayashi H., Koide S., Sato W., Yuzawa Y.: A retrospectivestudy on the outcomes of MPO-ANCA-associated vasculitis in dialysis–dependent patients. Mod. Rheumatol., 2016; 26: 110-114
  Google Scholar
• 40. Hiemstra T.F., Walsh M., Mahr A., Savage C.O., de Groot K., HarperL., Hauser T., Neumann I., Tesar V., Wissing K.M., Pagnoux C., SchmittW., Jayne D.R.: Mycophenolate mofetil vs azathioprine for remissionmaintenance in antineutrophil cytoplasmic antibody-associated vasculitis:a randomized controlled trial. JAMA, 2010; 304: 2381-2388
  Google Scholar
• 41. Hogan P.C., O’Connell R.M., Scollard S., Browne E., Hackett E.E.,Feighery C.: Biomarkers predict relapse in granulomatosis with polyangiitis.J. Biomark., 2014; 2014: 596503
  Google Scholar
• 42. Hu W., Liu C., Xie H., Chen H., Liu Z., Li L.: Mycophenolate mofetilversus cyclophosphamide for inducing remission of ANCA vasculitiswith moderate renal involvement. Nephrol. Dial. Transplant., 2008;23: 1307-1312
  Google Scholar
• 43. Jayne D.: Newer and future treatment of vasculitis. In: Textbookof systemic vasculitis, ed.: A. Sharma. Jaypee Brothers Medical Publishers,New Delhi 2015, 238-244
  Google Scholar
• 44. Jayne D.R, Chapel H., Adu D., Misbah S., O’Donoghue D., Scott D.,Lockwood C.M.: Intravenous immunoglobulin for ANCA-associated systemicvasculitis with persistent disease activity. QJM, 2000; 93: 433-439
  Google Scholar
• 45. Jayne D.R., Gaskin G., Rasmussen N., Abramowicz D., Ferrario F.,Guillevin L., Mirapeix E., Savage C.O., Sinico R.A., Stegeman C.A., WestmanK.W., van der Woude F.J., de Lind van Wijngaarden R.A., Pusey C.D.:Randomized trial of plasma exchange or high-dosage methylprednisoloneas adjunctive therapy for severe renal vasculitis. J. Am. Soc.Nephrol., 2007; 18: 2180-2188
  Google Scholar
• 46. Jayne D., Rasmussen N., Andrassy K., Bacon P., Tervaert J.W., DadonienéJ., Ekstrand A., Gaskin G., Gregorini G., de Groot K., Gross W.,Hagen E.C., Mirapeix E., Pettersson E., Siegert C., et al.: A randomizedtrial of maintenance therapy for vasculitis associated with antineutrophilcytoplasmic autoantibodies. N. Engl. J. Med., 2003; 349: 36-44
  Google Scholar
• 47. Jennette J.C., Falk R.J.: New insight into the pathogenesis of vasculitisassociated with antineutrophil cytoplasmic autoantibodies. Curr.Opin. Rheumatol., 2008; 20: 55-60
  Google Scholar
• 48. Jha V.: Renal and systemic vasculitis. In: Comprehensive ClinicalNephrology, eds.: J. Floege, R.J. Johnson, J. Feehally. Saunders, St. Louis,Missouri, 2010, 292-307
  Google Scholar
• 49. Jones R., Harper L., BallarinJ., Blockmans D., Brogan P., BruchfeldA., Cid A., Dahlsveen K.,Dezoysa J., Lanyon P., Peh C.A., Tesar V., VaglioA., Walsh M., Walsh D., et al.: A randomized trial of mycophenolatemofetil versus cyclophosphamide for remission induction of ANCA–associated vasculitis: “MYCYC”. On behalf of the European vasculitisstudy group [abstract]. Presse Med., 2013; 42: 678-679
  Google Scholar
• 50. Jones R.B., Furuta S., Tervaert J.W., Hauser T., Luqmani R., MorganM.D., Peh C.A., Savage C.O., Segelmark M., Tesar V., van Paassen P.,Walsh M., Westman K., Jayne D.R.: Rituximab versus cyclophosphamidein ANCA-associated renal vasculitis: 2-year results of a randomisedtrial. Ann. Rheum. Dis., 2015; 74: 1178-1182
  Google Scholar
• 51. Jones R.B., Tervaert J.W., Hauser T., Luqmani R., Morgan M.D., PehC.A., Savage C.O., Segelmark M., Tesar V., van Paassen P., Walsh D., WalshM., Westman K., Jayne D.R.: Rituximab versus cyclophosphamide inANCA-associated renal vasculitis. N. Engl. J. Med., 2010; 363: 211-220
  Google Scholar
• 52. Joy M.S., Hogan S.L., Jennette J.C., Falk R.J., Nachman P.H.: A pilotstudy using mycophenolate mofetil in relapsing or resistant ANCAsmall vessel vasculitis. Nephrol. Dial. Transplant., 2005; 20: 2725-2732
  Google Scholar
• 53. Kameoka Y., Kishi F., Yamakawa Y., Nagasawa R., Ikeda S., KouraM., Matsuda J., Nakayama T., Suzuki K.: Synthetic immunoglobulin selectedfrom clone library for MPO-ANCA-related vasculitis. Nephron,2015; 129: 145-146 (17th International Vasculitis & ANCA Workshop)
  Google Scholar
• 54. Karagas M.R., Cushing G.L. Jr, Greenberg E.R., Mott L.A., SpencerS.K., Nierenberg D.W.: Non-melanoma skin cancers and glucocorticoidtherapy. Br. J. Cancer, 2001; 85: 683-686
  Google Scholar
• 55. Knight A., Hallenberg H., Baecklund E.: Efficacy and safety of rituximabas maintenance therapy for relapsing granulomatosis withpolyangiitis – a case series. Clin. Rheumatol., 2014; 33: 841-848
  Google Scholar
• 56. Knoll G., Cockfield S., Blydt-Hansen T., Baran D., Kiberd B., LandsbergD., Rush D., Cole E.: Canadian Society of Transplantation consensusguidelines on eligibility for kidney transplantation. CMAJ, 2005;173: S1-S25
  Google Scholar
• 57. Komatsuda A., Omokawa A., Fujiwara T., Sato R, Togashi M, OkuyamaS,Sawada K, Wakui H.: Serum procalcitonin levels in patients withmyeloperoxidase-antineutrophil cytoplasmic antibodies-associatedglomerulonephritis. Am. J. Med. Sci., 2012; 343: 136-140
  Google Scholar
• 58. Kötter I., Daikeler T., Amberger C., Tyndall A., Kanz L.: Autologousstem cell transplantation of treatment-resistant systemic vasculitis – asingle center experience and review of the literature. Clin. Nephrol.,2005; 64: 485-489
  Google Scholar
• 59. Kusumoto S., Tanaka Y., Ueda R., Mizokami M.: Reactivation ofhepatitis B virus following rituximab-plus-steroid combination chemotherapy.J. Gastroenterol., 2011; 46: 9-16
  Google Scholar
• 60. Lieberthal J.G., Cuthbertson D., Carette S., Hoffman G.S., KhalidiN.A., Koening C.L., Langford C.A., Maksimowicz-McKinnon K., Seo P.,Specks U., Ytterberg S.R., Merkel P.A., Monach P.A.: Urinary markers inrelapsing antineutrophil cytoplasmic antibody-associated vasculitis.J. Rheumatol., 2013; 40: 674-683
  Google Scholar
• 61. Lionaki S., Hogan S.L., Jennette C.E., Hu Y., Hamra J.B., JennetteJ.C., Falk R.J., Nachman P.H.: The clinical course of ANCA small-vesselvasculitis on chronic dialysis. Kidney Int., 2009; 76: 644-651
  Google Scholar
• 62. Little M.A., Pusey C.D.: Glomerulonephritis due to antineutrophilcytoplasm antibody-associated vasculitis: an update on approaches tomanagement. Nephrology, 2005; 10: 368-376
  Google Scholar
• 63. Lovric S., Erdbruegger U., Kümpers P., Woywodt A., Koenecke C.,Wedemeyer H., Haller H., Haubitz M.: Rituximab as rescue therapy inanti-neutrophil cytoplasmic antibody-associated vasculitis: a single–centre experience with 15 patients. Nephrol. Dial. Transplant., 2009;24: 179-185
  Google Scholar
• 64. Mansfield N., Hamour S., Habib A.M., Tarzi R., Levy J., Griffith M.,Cairns T., Cook H.T., Pusey C.D., Salama A.D.: Prolonged disease-freeremission following rituximab and low-dose cyclophosphamide therapyfor renal ANCA-associated vasculitis. Nephrol. Dial. Transplant.,2011; 26: 3280-3286
  Google Scholar
• 65. Marco H., Smith R.M., Jones R.B., Guerry M.J., Catapano F., Burns S.,Chaudhry A.N., Smith K.G., Jayne D.R.: The effect of rituximab therapyon immunoglobulin levels in patients with multisystem autoimmunedisease. BMC Musculoskelet. Disord., 2014; 15: 178
  Google Scholar
• 66. McAdoo S., Bedi R., Tarzi R., Griffith M., Pusey C., Cairns T.: Ofatumumabfor B cell depletion therapy in ANCA-asociated vasculitis.Nephron, 2015; 129: 111-112 (17th International Vasculitis & ANCAWorkshop)
  Google Scholar
• 67. McAdoo S.P., Reynolds J., Bhangal G., Smith J., McDaid J.P., TannaA., Jackson W.D., Masuda E.S., Cook H.T., Pusey C.D., Tam F.W.: Spleentyrosine kinase inhibition attenuates autoantibody production andreverses experimental autoimmune GN. J. Am. Soc. Nephrol., 2014;25: 2291-2302
  Google Scholar
• 68. McGregor J.G., Hogan S.L., Hu Y., Jennette C.E., Falk R.J., NachmanP.H.: Glucocorticoids and relapse and infection rates in anti-neutrophilcytoplasmic antibody disease. Clin. J. Am. Soc. Nephrol., 2012; 7: 240-247
  Google Scholar
• 69. McGregor J.G., Hogan S.L., Kotzen E.S., Poulton C.J., Hu Y., Negrete-LopezR., Kidd J.M., Katsanos S.L., Bunch D.O., Nachman P.H., FalkR.J.: Rituximab as an immunosuppressant in antineutrophil cytoplasmicantibody-associated vasculitis. Nephrol. Dial. Transplant., 2015;30: 123-131
  Google Scholar
• 70. Medical Outcomes Study: 36-Item Short Form Survey Instrument.http://www.rand.org/health/surveys_tools/mos/mos_core_36item_survey.html (28.02.2016)
  Google Scholar
• 71. Metzler C., Miehle N., Manger K., Iking-Konert C., de Groot K.,Hellmich B., Gross W.L., Reinhold-Keller E.: Elevated relapse rate underoral methotrexate versus leflunomide for maintenance of remissionin Wegener’s granulomatosis. Rheumatology, 2007; 46: 1087-1091
  Google Scholar
• 72. Miloslavsky E.M., Specks U., Merkel P.A., Seo P., Spiera R., LangfordC.A., Hoffman G.S., Kallenberg C.G., St Clair E.W., Tchao N.K., VivianoL., Ding L., Iklé D., Villarreal M., Jepson B., et al.: Rituximab for the treatmentof relapses in antineutrophil cytoplasmic antibody-associatedvasculitis. Arthritis Rheumatol., 2014; 66: 3151-3159
  Google Scholar
• 73. Miloslavsky E.M., Specks U., Merkel P.A., Seo P., Spiera R., LangfordC.A., Hoffman G.S., Kallenberg C.G., St Clair E.W., Tchao N.K., VivianoL., Ding L., Sejismundo L.P., Mieras K., Iklé D., et al.: Clinical outcomesof remission induction therapy for severe antineutrophil cytoplasmicantibody-associated vasculitis. Arthritis Rheum., 2013; 65: 2441-2449
  Google Scholar
• 74. Mohammad A.J., Hot A., Arndt F., Moosig F., Guerry M.J., AmudalaN., Smith R., Sivasothy P., Guillevin L., Merkel P.A., Jayne D.R.: Rituximabfor the treatment of eosinophilic granulomatosis with polyangiitis(Churg-Strauss). Ann. Rheum. Dis., 2016; 75: 396-401
  Google Scholar
• 75. Molloy E.S., Calabrese L.H.: Progressive multifocal leukoencephalopathyassociated with immunosuppressive therapy in rheumaticdiseases: evolving role of biologic therapies. Arthritis. Rheum., 2012;64: 3043-3051
  Google Scholar
• 76. Moran S., Little M.A.: Renal transplantation in antineutrophilcytoplasmic antibody-associated vasculitis. Curr. Opin. Rheumatol.,2014; 26: 37-41
  Google Scholar
• 77. Mukhtyar C., Guillevin L., Cid M.C., Dasgupta B., de Groot K., GrossW., Hauser T., Hellmich B., Jayne D., Kallenberg C.G., Merkel P.A., RaspeH., Salvarani C., Scott D.G., Stegeman C., et al.: EULAR recommendationsfor the management of primary small and medium vessel vasculitis.Ann. Rheum. Dis., 2009; 68: 310-317
  Google Scholar
• 78. Nachman P.H., Denu-Ciocca C.J.: Vasculitides. In.: Current Diagnosisand Treatment, eds.: E.V. Lerma, J.S. Bern, A.R. Nissenson. McGraw-Hill,New York 2008, 265-275
  Google Scholar
• 79. Nachman P.H., Hogan S.L., Jennette J.C., Falk R.J.: Treatment responseand relapse in antineutrophil cytoplasmic autoantibody-associatedmicroscopic polyangiitis and glomerulonephritis. J. Am. Soc.Nephrol. 1996; 7: 33-39
  Google Scholar
• 80. Nowack R., Göbel U., Klooker P., Hergesell O., Andrassy K., vander Woude F.J.: Mycophenolate mofetil for maintenance therapy ofWegener’s granulomatosis and microscopic polyangiitis: a pilot studyin 11 patients with renal involvement. J. Am. Soc. Nephrol., 1999;10: 1965-1971
  Google Scholar
• 81. Ntatsaki E., Carruthers D., Chakravarty K., D’Cruz D., Harper L.,Jayne D., Luqmani R., Mills J., Mooney J., Venning M., Watts R.A.: BSRand BHPR Standards, Guidelines and Audit Working Group. BSR andBHPR guideline for the management of adults with ANCA-associatedvasculitis. Rheumatology, 2014; 53: 2306-2309
  Google Scholar
• 82. Pagnoux C., Mahr A., Hamidou M.A., Boffa J.J., Ruivard M., DucroixJ.P., Kyndt X., Lifermann F., Papo T., Lambert M., Le Noach J., KhellafM., Merrien D., Puéchal X., Vinzio S., et al.: Azathioprine or methotrexatemaintenance for ANCA-associated vasculitis. N. Engl. J. Med.,2008; 359: 2790-2803
  Google Scholar
• 83. Pepper R.J., Draibe J., Tchao N., Lim N., Stone J., Specks U., MerkelP., Salama A.D.: The association of serum calprotectin (S100A8/S100A9)levels with disease relapse in PR3-ANCA-associated vasculitis. Nephron,2015; 129: 95-96 (17th International Vasculitis & ANCA Workshop)
  Google Scholar
• 84. Pepper R.J., Fabre M.A., Pavesio C., Gaskin G., Jones R.B., Jayne D.,Pusey C.D., Salama A.D.: Rituximab is effective in the treatment of refractoryChurg-Strauss syndrome and is associated with diminishedT-cell interleukin-5 production. Rheumatology, 2008; 47: 1104-1105
  Google Scholar
• 85. Perenyei M., Jayne D.R., Floβmann O.: Gusperimus: immunologicalmechanism and clinical applications. Rheumatology, 2014; 53:1732-1741
  Google Scholar
• 86. Puéchal X., Pagnoux C., Perrodeau E., Hamidou M., Boffa J., KnydtX., Liferman F., Papo T., Merrien D., Smail A., Delaval P., Hanrotel-SaliouC., Imbert B., Khouatra C., Lambert M.: Granulomatosis with polyangiitisor microscopic polyangiitis: longterm outcomes of the prospectiveWEGENT trial comparing azathioprine vsmethotrexate for remission–maintainance in 126 patients. Nephron, 2015; 129: 80 (17th InternationalVasculitis & ANCA Workshop)
  Google Scholar
• 87. Pullerits R., Ljevak M., Vikgren J., Bokarewa M.: Off-trial evaluationof the B cell-targeting treatment in the refractory cases of antineutrophilcytoplasmic antibodies (ANCA)-associated vasculitis: long-termfollow-up from a single centre. Scand. J. Immunol., 2012; 76: 411-420
  Google Scholar
• 88. Rathi M., Sharma A., Nada R.: Renal manifestations. In: Textbookof systemic vasculitis, ed.: A. Sharma. Jaypee Brothers Medical Publishers,New Delhi 2015, 157-163
  Google Scholar
• 89. Rees F., Yazdani R., Lanyon P.: Long-term follow-up of differentrefractory systemic vasculitides treated with rituximab. Clin. Rheumatol.,2011; 30: 1241-1245
  Google Scholar
• 90. Rhee E.P., Laliberte K.A., Niles J.L.: Rituximab as maintenance therapy for anti-neutrophil cytoplasmic antibody-associated vasculitis.Clin. J. Am. Soc. Nephrol., 2010; 5: 1394-1400
  Google Scholar
• 91. Roccatello D., Sciascia S., Rossi D., Alpa M., Naretto C., Russo A.,Menegatti E., Baldovino S.: Long-term effects of rituximab added tocyclophosphamide in refractory patients with vasculitis. Am. J. Nephrol.,2011; 34: 175-180
  Google Scholar
• 92. Saag K.G., Furst D.E.: Major side effects of systemic glucocorticoids.In: UpToDate, ed.: E.L. Matteson. UpToDate, Waltham, Massachusetts
  Google Scholar
• 93. Savige J., Gillis D., Benson E., Davies D., Esnault V., Falk R.J., HagenE.C., Jayne D., Jennette J.C., Paspaliaris B., Pollock W., Pusey C., SavageC.O., Silvestrini R., van der Woude F., et al.: International ConsensusStatement on Testing and Reporting of Antineutrophil CytoplasmicAntibodies (ANCA). Am. J. Clin. Pathol., 1999; 111: 507-513
  Google Scholar
• 94. Schmitt W.H., Hagen E.C., Neumann I., Nowack R., Flores-SuárezL.F., van der Woude F.J.: Treatment of refractory Wegener’s granulomatosiswith antithymocyte globulin (ATG): an open study in 15 patients.Kidney Int., 2004; 65: 1440-1448
  Google Scholar
• 95. Schönermarck U., Gross W.L., de Groot K.: Treatment of ANCA-associatedvasculitis. Nat. Rev. Nephrol., 2014; 10: 25-36
  Google Scholar
• 96. Seo P., Min Y.I., Holbrook J.T., Hoffman G.S., Merkel P.A., Spiera R.,Davis J.C., Ytterberg S.R., St Clair E.W., McCune W.J., Specks U., AllenN.B., Luqmani R.A., Stone J.H.: Damage caused by Wegener’s granulomatosisand its treatment: prospective data from the Wegener’sGranulomatosis Etanercept Trial (WGET). Arthritis Rheum., 2005; 52:2168-2178
  Google Scholar
• 97. Silva F., Specks U., Kalra S., Hogan M.C., Leung N., Sethi S., FervenzaF.C.: Mycophenolate mofetil for induction and maintenanceof remission in microscopic polyangiitis with mild to moderate renalinvolvement – a prospective, open-label pilot trial. Clin. J. Am. Soc.Nephrol., 2010; 5: 445-453
  Google Scholar
• 98. Sitter T., Schmidt M., Schneider S., Schiffl H.: Differential diagnosisof bacterial infection and inflammatory response in kidney diseasesusing procalcitonin. J. Nephrol. 2002; 15: 297-301
  Google Scholar
• 99. Smith R.M., Jones R.B., Guerry M.J., Laurino S., Catapano F., ChaudhryA., Smith K.G., Jayne D.R.: Rituximab for remission maintenancein relapsing antineutrophil cytoplasmic antibody-associated vasculitis.Arthritis Rheum., 2012; 64: 3760-3769
  Google Scholar
• 100. Specks U., Merkel P.A., Seo P., Spiera R., Langford C.A., HoffmanG.S., Kallenberg C.G., St Clair E.W., Fessler B.J., Ding L., Viviano L., TchaoN.K., Phippard D.J., Asare A.L., Lim N., et al.: Efficacy of remission–induction regimens for ANCA-associated vasculitis. N. Engl. J. Med.,2013; 369: 417-427
  Google Scholar
• 101. Stassen P.M., Tervaert J.W., StegemanC.A.: Induction of remissionin active anti-neutrophil cytoplasmic antibody-associated vasculitiswith mycophenolate mofetil in patients who cannot be treated withcyclophosphamide. Ann. Rheum. Dis., 2007; 66: 798-802
  Google Scholar
• 102. Statkute L., Oyama Y., Barr W.G., Sufit R., Ho S., Verda L., Loh Y.,Yaung K., Quigley K., Burt R.K.: Autologous non-myeloablative haematopoieticstem cell transplantation for refractory systemic vasculitis.Ann. Rheum. Dis., 2008; 67: 991-997
  Google Scholar
• 103. Stone J.H., Merkel P.A., Spiera R., Seo P., Langford C.A., HoffmanG.S., Kallenberg C.G., St Clair E.W., Turkiewicz A., Tchao N.K., WebberL., Ding L., Sejismundo L.P., Mieras K., Weitzenkamp D., et al.: Rituximabversus cyclophosphamide for ANCA-associated vasculitis. N. Engl.J. Med., 2010; 363: 221-232
  Google Scholar
• 104. Suppiah R., Mukhtyar C., Flossmann O., Alberici F., Baslund B.,Batra R., Brown D., Holle J., Hruskova Z., Jayne D.R., Judge A., LittleM.A., Palmisano A., Stegeman C., Tesar V., et al.: A cross-sectional studyof the Birmingham Vasculitis Activity Score version 3 in systemicvasculitis. Rheumatology, 2011; 50: 899-905
  Google Scholar
• 105. Tang W., Bose B., McDonald S.P., Hawley C.M., Badve S.V., BoudvilleN., Brown F.G., Clayton P.A., Campbell S.B., Peh C.A., Johnson D.W.:The outcomes of patients with ESRD and ANCA-associated vasculitis inAustralia and New Zealand. Clin. J. Am. Soc. Nephrol., 2013; 8: 773-780
  Google Scholar
• 106. Terrier B., Pagnoux C., Karras A., Khouatra C., Aumaitre O., CohenP., Maurier F., Decaux O., Demurs-Clavel H., Gobert P.: Rituximabversus azathioprine for maintenance in antineutrophil cytoplasmicantibodies (ANCA)-associated vasculitis (MAINRITSAN): Follow-up at 34 months. La Presse Médicale, 2013; 42: 778-779 (16th InternationalVasculitis & ANCA Workshop)
  Google Scholar
• 107. Thai L.H., Charles P., Resche-Rigon M., Desseaux K., Guillevin L.:Are antiproteinase-3 ANCA a useful marker of granulomatosis withpolyangiitis (Wegener’s) relapses? Results of a retrospective study on 126 patients. Autoimmun. Rev., 2014; 13: 313-318
  Google Scholar
• 108. Thiel J., Hässler F, Salzer U., Voll R.E., Venhoff N.: Rituximab inthetreatment of refractory or relapsing eosinophilic granulomatosiswithpolyangiitis (Churg-Strauss syndrome). Arthritis Res. Ther.,2013; 15: R133
  Google Scholar
• 109. Tomasson G., Grayson P.C., Mahr A.D., Lavalley M., Merkel P.A.:Value of ANCA measurements during remission to predict a relapseof ANCA-associated vasculitis – a meta-analysis. Rheumatology, 2012;51: 100-109
  Google Scholar
• 110. US National Library of Medicine. Clinicaltrials.gov. Belimumabin Remission of VASculitis (BREVAS). http://clinicaltrials.gov/show/NCT01663623 (28.02.2016)
  Google Scholar
• 111. US National Library of Medicine. Clinicaltrials.gov. ComparisonStudy of Two Rituximab Regimens in the Remission of ANCA AssociatedVasculitis (MAINRITSAN 2). http://clinicaltrials.gov/ct2/show/NCT01731561?term=MAINRITSAN%27&rank=2 (28.02.2016)
  Google Scholar
• 112. US National Library of Medicine. Clinicaltrials.gov. RituximabVasculitis Maintenance Study (RITAZAREM). http://clinicaltrials.gov/ct2/show/NCT01697267 (28.02.2016)
  Google Scholar
• 113. van Daalen E., Ferrario F., Noël L.H., Waldherr R. Hagen E.C., BruijnJ.A., Bajema I.M.: Twenty-five years of RENHIS: a history of histopathologicalstudies within EUVAS. Nephrol. Dial. Transplant., 2015; 30: 31-36
  Google Scholar
• 114. Walsh M., Casian A., Flossmann O., Westman K., Höglund P., PuseyC., Jayne D.R.: Long-term follow-up of patients with severe ANCA-associatedvasculitis comparing plasma exchange to intravenous methylprednisolonetreatment is unclear. Kidney Int., 2013; 84: 397-402
  Google Scholar
• 115. Walsh M., Chaudhry A., Jayne D.: Long-term follow-up of relapsing/refractoryanti-neutrophil cytoplasm antibody associated vasculitistreated with the lymphocyte depleting antibody alemtuzumab(CAMPATH-1H). Ann. Rheum. Dis. 2008; 67: 1322-1327
  Google Scholar
• 116. Walsh M., Merkel P.A., Peh C.A., Szpirt W., Guillevin L., Pusey C.D.,De Zoysa J., Ives N., Clark W.F., Quillen K., Winters J.L., Wheatley K., JayneD.: Plasma exchange and glucocorticoid dosing in the treatment ofanti-neutrophil cytoplasm antibody associated vasculitis (PEXIVAS):protocol for a randomized controlled trial. Trials, 2013; 14: 73
  Google Scholar
• 117. Weiner M., Goh S.M., Mohammad A.J., Hruskova Z., Tanna A.,Bruchfeld A., Selga D., Chocova Z., Westman K., Eriksson P., Pusey C.D.,Tesar V., Salama A.D., Segelmark M.: Outcome and treatment of elderlypatients with ANCA-associated vasculitis. Clin. J. Am. Soc. Nephrol.,2015; 10: 1128-1135
  Google Scholar
• 118. Wendt M., Gunnarsson I., Bratt J., Bruchfeld A.: Rituximab inrelapsing or refractory ANCA-associated vasculitis: a case series of 16patients. Scand. J. Rheumatol., 2012; 41: 116-119
  Google Scholar
• 119. Williams M.E., Balogun R.A.: Principles of separation: indicationsand therapeutic targets for plasma exchange. Clin. J. Am. Soc. Nephrol.,2014; 9: 181-190
  Google Scholar
• 120. Xiao H., Dairaghi D.J., Powers J.P., Ertl L.S., Baumgart T., Wang Y.,Seitz L.C., Penfold M.E., Gan L., Hu P., Lu B., Gerard N.P., Gerard C., SchallT.J., Jaen J.C., Falk R.J.: C5a receptor (CD88) blockade protects againstMPO-ANCA GN. J. Am. Soc. Nephrol., 2014; 25: 225-231
  Google Scholar

Pełna treść artykułu